Premium
Novel Mechanism of Cathepsin B Inhibition by Antibiotic Nitroxoline and Related Compounds
Author(s) -
Mirković Bojana,
Renko Miha,
Turk Samo,
Sosič Izidor,
Jevnikar Zala,
Obermajer Nataša,
Turk Dušan,
Gobec Stanislav,
Kos Janko
Publication year - 2011
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201100098
Subject(s) - cathepsin b , cathepsin , antimicrobial , cathepsin s , mechanism (biology) , chemistry , cathepsin e , cancer research , antibiotics , cancer , microbiology and biotechnology , pharmacology , enzyme , medicine , cathepsin o , biology , biochemistry , philosophy , epistemology
A new trick for an old dog! Aberrant cathepsin B activity is associated with tumor progression, however, despite extensive research, there are no cathepsin B inhibitors in clinical use. Here, nitroxoline, an established antimicrobial agent, is identified as a potent, reversible inhibitor of cathepsin B, and is thus a potential drug candidate for the treatment of cancer and other diseases in which cathepsin B activity plays a role.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom